News Sentiment

ALNY sentiment intelligence

Alnylam Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 267.47 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.5% over one week, -3.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

US2043QAC1 Bond Profile — Key Metrics

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction -10.5% Price reacting lower
Trend fit Trend inactive -3.8% over four weeks
Fair value -1.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 34
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Investing.com 5
simplywall.st 5
Simply Wall Street 4
Moomoo 4
TradingView 3
Quartr 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 18
Analyst action 11
Guidance 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Sahm Direct company coverage

Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure

Alnylam Pharmaceuticals (ALNY) surged after a competitor's transthyretin amyloid cardiomyopathy treatment failed a late-stage trial, shifting focus to Alnylam's ATTR portfolio. Despite a year-to-date share price decline of 21.84%, the stock is considered 28% undervalued by Simply

Tone
Positive 72/100
Event
Market update
Published
12 Jul 2026 00:09
Source
Sahm
TradingView Direct company coverage

Alnylam Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $446.43, Implies 38% Upside

Alnylam Pharmaceuticals, Inc.'s average 12-month stock price target has increased from $443.04 to $446.43, according to 23 analyst estimates, suggesting a potential 38% upside from its July 8 closing price. The consensus rating from 30 analysts remains "Buy," with 22 buy ratings,

Tone
Positive 74/100
Event
Analyst action
Published
10 Jul 2026 00:39
Source
TradingView